While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. more...
Like other research-based pharmaceutical companies, Daiichi Sankyo is engaged in high-risk/high-return research and development investments. more...
Besides the company's world headquarters in Tokyo, the Daiichi Sankyo Group has affiliates in almost 60 countries and in all continents. Its German and European base is located in Munich. more...
Daiichi Sankyo Europe has two production facilities, both approved by national and international authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and... more...
Latest news
-
Daiichi Sankyo posted results for financial year 2011
Daiichi Sankyo and its consolidated subsidiaries (“the Group”) posted consolidated net sales for the fiscal year ended March 31, 2012 (FY2011) of ¥938.7 billion, a year-on-year fall of 3.0%. more...
-
Ranbaxy Launches Atorvastatin in Germany
The German subsidiary of Ranbaxy Laboratories Limited, Basics GmbH, launched Atorvastatin Basics®, a generic version of the cholesterol lowering drug Sortis®*, in the German market. Ranbaxy, headquartered in Gurgaon, India, has an agreement with Pfizer for rights to an early entry of Atorvastatin in the German market. Pfizer’s patent for Sortis® expires in Germany on 7th May 2012. more...
-
Daiichi Sankyo and GSK establish Vaccine Joint Venture in Japan
Daiichi Sankyo and the British Pharmaceutical Company GlaxoSmithKline (GSK) have agreed to enter into a strategic alliance in vaccines business and will form a Vaccine Joint Venture in Japan. The Joint Venture will be named Japan Vaccine Co., Ltd. GSK and Daiichi Sankyo will invest equally to that Joint Venture. more...